Ad­verum soars on ear­ly gene ther­a­py da­ta; BerGen­Bio rais­es €45.4M on the heels of Covid-19 move

→ An­oth­er cut of pos­i­tive in­ter­im da­ta have lift­ed ex­pec­ta­tions that Ad­verum’s gene ther­a­py that could give the an­ti-VEGF de­vel­op­ers a run for their mon­ey in wet AMD. In a Phase I tri­al, in­ves­ti­ga­tors re­port­ed that the first two co­horts con­tin­ue to re­spond to treat­ment, with the ma­jor­i­ty still free of res­cue in­jec­tions, while the third co­hort ex­pe­ri­enced few­er side ef­fects, pre­sum­ably be­cause they were giv­en top­i­cal steroids rather than oral steroids.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.